



## Clinical trial results:

### Allogeneic Stem Cell Transplantation of CordIn™, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients with Hemoglobinopathies

#### Summary

EudraCT number	2014-003572-23
Trial protocol	FR
Global end of trial date	20 November 2018

#### Results information

Result version number	v1 (current)
This version publication date	27 November 2019
First version publication date	27 November 2019

#### Trial information

##### Trial identification

Sponsor protocol code	GCP#01.01.030
-----------------------	---------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02504619
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Gamida Cell
Sponsor organisation address	5 Nahum Hafzadi, Givat Shaul, Jerusalem, Israel, 9548401
Public contact	Clinical Trial department, Gamida Cell Ltd, 972 26595666, kelly@gamida-cell.com
Scientific contact	Clinical Trial department, Gamida Cell Ltd, 026595631 26595666, kelly@gamida-cell.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	15 April 2019
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	20 November 2018
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

Assess the acute toxicities associated with the infusion of Omidubicel, formerly known as CordIn, within 24 hours post-infusion

Assess the proportion of patients with donor-derived engraftment at 42 days following transplantation

Protection of trial subjects:

The protocol was reviewed by institutional review boards at the study sites and approved by relevant health authorities. Patients were enrolled after a formal informed consent process. The study was conducted within the principles of good clinical practice. An independent data monitoring committee was in place in order to review toxicity data in individual patients.

Background therapy:

The Preparative Phase consisted of:

Hydroxyurea: 30mg/kg/day orally on days -35 to -13

The conditioning regimen consisted of:

Busulfan: 1mg/kg/dose IV q 6h on days -12 to -9 for 16 doses

Thiotepa: 5mg/kg/day on days -8 and -7

Fludarabine: 40mg/m<sup>2</sup>/day on days -6, -5, -4, and -3

The GvHD prophylaxis regimen was:

Mycophenolate Mofetil (MMF) beginning day -3 for at least 90 days and Cyclosporine: beginning day -3 to at least nine months post transplant

Evidence for comparator:

N/A as single arm study

Actual start date of recruitment	04 April 2016
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	United States: 1
Worldwide total number of subjects	1
EEA total number of subjects	0

Notes:

### Subjects enrolled per age group

In utero	0
----------	---

Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	1
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

France was open for recruitment in June 2015 followed by the US where one patient was recruited in April 2016.

### Pre-assignment

Screening details:

2 subjects were assessed for eligibility. One subject was excluded for clinically significant iron overload.

### Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

### Arms

<b>Arm title</b>	CordIn
------------------	--------

Arm description:

Underwent hematopoietic stem cell transplantation with CordIn graft

Arm type	Experimental
Investigational medicinal product name	CordIn
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Dispersion for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Dosage is administered once

<b>Number of subjects in period 1</b>	CordIn
Started	1
Completed	1

## Baseline characteristics

---

### Reporting groups

Reporting group title

Overall trial

Reporting group description: -

Reporting group values	Overall trial	Total	
Number of subjects	1	1	
Age categorical Units: Subjects			
Children (2-11 years)	1	1	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	0	0	
Gender categorical Units: Subjects			
Female	0	0	
Male	1	1	

## End points

### End points reporting groups

Reporting group title	CordIn
Reporting group description:	
Underwent hematopoietic stem cell transplantation with CordIn graft	

### Primary: proportion of patients with donor-derived engraftment

End point title	proportion of patients with donor-derived engraftment <sup>[1]</sup>
End point description:	

End point type	Primary
End point timeframe:	
42 days post transplant	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: only 1 patient was evaluated.

End point values	CordIn			
Subject group type	Reporting group			
Number of subjects analysed	1			
Units: percent				
number (not applicable)	100			

### Statistical analyses

No statistical analyses for this end point

### Primary: Proportion of patients with acute toxicities associated with the infusion of CordIn

End point title	Proportion of patients with acute toxicities associated with the infusion of CordIn <sup>[2]</sup>
End point description:	

End point type	Primary
End point timeframe:	
24 hours post transplant	

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: only 1 patient was evaluated.

End point values	CordIn			
Subject group type	Reporting group			
Number of subjects analysed	1			
Units: percent				
number (not applicable)	0			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Cumulative incidence of transplant-related mortality

End point title	Cumulative incidence of transplant-related mortality
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

day 100 post-transplant

End point values	CordIn			
Subject group type	Reporting group			
Number of subjects analysed	1			
Units: percent				
number (not applicable)	0			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Event-free survival

End point title	Event-free survival
-----------------	---------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

day 100 post-transplant

End point values	CordIn			
Subject group type	Reporting group			
Number of subjects analysed	1			
Units: percent				
number (not applicable)	100			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Event-free survival

End point title	Event-free survival
End point description:	
End point type	Secondary
End point timeframe:	
One year post-transplant	

End point values	CordIn			
Subject group type	Reporting group			
Number of subjects analysed	1			
Units: percent				
number (not applicable)	100			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Overall survival

End point title	Overall survival
End point description:	
End point type	Secondary
End point timeframe:	
One year post-transplant	



End point values	CordIn			
Subject group type	Reporting group			
Number of subjects analysed	1			
Units: percent				
number (not applicable)	100			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Proportion of treatment free HbS ≤ 30%

End point title	Proportion of treatment free HbS ≤ 30%
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

One year post-transplant

End point values	CordIn			
Subject group type	Reporting group			
Number of subjects analysed	1			
Units: percent				
number (not applicable)	100			

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

up to 1 year post-transplant

Adverse event reporting additional description:

Grade 2/3 Infections & GvHD reported to 1 year post-transplant.

All common events post-transplant collected to day 42 post-transplant. Grade 3-4 non-serious AEs reported to 1 year post-transplant.

The list below includes grade ≥3 AEs only. Occurrences not collected (only highest grade over each specified period). Default number entered.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	21
--------------------	----

### Reporting groups

Reporting group title	General
-----------------------	---------

Reporting group description: -

Serious adverse events	General		
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 1 (100.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	1 / 1 (100.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Immune system disorders			
Graft versus host disease	Additional description: includes both graft versus host disease and acute graft versus host disease.		
subjects affected / exposed	1 / 1 (100.00%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Hallucination			
subjects affected / exposed	1 / 1 (100.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 3 %

<b>Non-serious adverse events</b>	General		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	1 / 1 (100.00%)		
Investigations			
Mucositis			
subjects affected / exposed	1 / 1 (100.00%)		
occurrences (all)	1		
Vascular disorders			
Hypertension			
subjects affected / exposed	1 / 1 (100.00%)		
occurrences (all)	1		
Hypotension			
subjects affected / exposed	1 / 1 (100.00%)		
occurrences (all)	1		
Cardiac disorders			
Cardiac arrhythmias			
subjects affected / exposed	1 / 1 (100.00%)		
occurrences (all)	1		
Blood and lymphatic system disorders			
Hypoalbuminaemia			
subjects affected / exposed	1 / 1 (100.00%)		
occurrences (all)	1		
General disorders and administration site conditions			
Pain			
subjects affected / exposed	1 / 1 (100.00%)		
occurrences (all)	1		
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	1 / 1 (100.00%)		
occurrences (all)	1		
Vomiting			

subjects affected / exposed occurrences (all)	1 / 1 (100.00%) 1		
Hepatobiliary disorders Elevated liver transaminases subjects affected / exposed occurrences (all)	1 / 1 (100.00%) 1		
Infections and infestations Fever subjects affected / exposed occurrences (all)	1 / 1 (100.00%) 1		
Metabolism and nutrition disorders Anorexia subjects affected / exposed occurrences (all)	1 / 1 (100.00%) 1		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
08 December 2014	Clarification on supportive care therapy for inclusion criteria
27 March 2015	Update of CBU selection and product release criteria. Removal of Conditioning regimen B
24 June 2015	<ul style="list-style-type: none"><li>- Addition of SCD eligibility committee approval requirement</li><li>- Additional options for back-up stem cell source</li><li>- Additional eligibility criteria</li><li>- Clarification of infection monitoring, GvHD prophylaxis, eligibility criteria</li></ul>

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported